Overview

Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
To study the efficacy and safety of pitavastatin and PCSK9 inhibitors in liver transplant patients on ongoing immunosuppressive therapy.
Phase:
Phase 4
Details
Lead Sponsor:
National Medical Research Center for Therapy and Preventive Medicine
Treatments:
Pitavastatin